Navigation Links
Antibodies for Studying NMDA Receptor Protein Expression and,,,Synapse-Specific Immunolabeling

New antibodies for neuroscience research


Danny Q. Hoang Michael Browning Xinping Yang Peter Pingerelli
Stratagene Cloning Systems, Inc.


Stratagene introduces affinity purified antibodies for NMDA receptor subunits that are useful for studying expression of the NR2A, NR2B and NR2C subunit proteins in different cell types and brain regions. These antibodies have been used in Western blot analysis of rat brain to study expression of specific NMDA receptor subunits. In addition, these antibodies can be used for immunoprecipitation and immunohistochemistry. Stratagene also introduces an antibody for synapsin I, the synapse-specific protein, that is useful for studying synaptogenesis and synapse elimination.

Glutamate is a major excitatory neurotransmitter in the mammalian central nervous system. The ion channels activated by glutamate are typically divided into two classes. Those that are sensitive to N-methyl-D-aspartate (NMDA) are designated NMDA receptors (NMDAR) while those activated by kainate and a-amino-3-hydroxy-5-methyl-4-isoxalone propionic acid (AMPA) are known as kainate/AMPA receptors (K/AMPAR). The NMDAR plays a critical role in long-term potentiation (LTP), a putative cellular substrate of memory.1 This receptor has also been linked to conditions involving injury neurotoxicity and in pathological states, such as epilepsy and Parkinsons, Huntingtons and Alzheimers diseases.2

Molecular cloning studies indicate that five NMDA receptor genes exist, including NMDAR1 (NR1) and four NR2 subunits (NR2A-D).3 When reconstituted in vitro, the functional properties of neuronal NMDAR appear to be conferred by the combination of an NR1 subunit with any of the four NR2 subunits.4 In addition, there are a number of different splice variants of the N
'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. Simple, Sensitive Isotyping of Mouse Monoclonal Antibodies
2. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
3. Enzyme Immunoassay for Studying Intracellular Levels of cAMP
4. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
5. New Fusion Trans-Activator Plasmids for Studying Signal Transduction Pathways
6. Detecting Gastrin-Releasing Peptide Receptor by in situ PCR on Archived Tissue
7. pFB-ERV: Retroviral Delivery of the Ecdysone Receptor Proteins
8. Gene-Specific Primers for NMDA Receptor Subunits
9. TKB1 Cells Identify Receptor Tyrosine Kinase Interacting Proteins
10. Quantification of the Purinergic Receptor P2X3 using ICAT and Orthogonal 2D LC-MS/MS with an Ion Trap Mass Spectrometer
11. Isolation of Low Molecular Weight Digestion Products of the Human Platelet Thromboxane A2 Receptor, Rev A

Post Your Comments:
(Date:11/6/2009)...Nov. 6 ,, 3Q09 Cor...Qutenza(TM) E.U. Marketing Authorization to Astell...in commercial readiness activities Expanded manag...arketing; and Director, Commercial Operations App...d Audit Committee chairman , Upcoming 2009 ...
(Date:11/6/2009)... The agenda for Arrowhead’s 2010 Personalize...o take place on February 22-24, 2010 in Philadelph...ce we will highlight key issues in forming partner...experiences. , Minneapoli...rrowhead’s 2010 Personalized Medicine Partn...
(Date:11/5/2009)...ov. 5 DSM Pharmaceutical Products ...lliance with Galenix, Saint Jean D,Illac, France, ...anufacturing partner for Galenix commercial produc...ollaborate on business development opportunities c...sed on the strength of Galenix in drug product dev...
(Date:11/5/2009)... Transgenomic, Inc. (OTC...esults for the quarter ended September 30, 2009. T...e tables that follow. ,, Third Quarter 2009 ,...r $0.01 per share for the third quarter of 2009 as...hare for the third quarter of 2008. ,, Net sal...
Breaking Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7
...on (Nasdaq: DNDN ) announced today the closing o...ring of 10,700,000 shares of its common stock, whi...19.20 per share. On May 8, 2009, Deutsche Bank Se...ing, exercised in full its over-allotment option t...n stock at the public offering price of $19.20 per...
...A has approved an,Investigational New Drug (IND) a... phase I clinical study with its selective PLK-1 s...r. PLK-1 is a mitotic kinase required for,the prol...ally bioavailable,highly efficient and well tolera... dosing. This unique inhibitor adds another promis...
...nc. (Xennex) announced today a major leap for Gene...ilable at http://www.genecards.org/v3 . , , ...ntly upgraded infrastructure, including a comprehe... sophisticated and speedier search engine. It prov...rgeted queries, a user-friendly display and clear ...
Other Biology Technology:Dendreon Announces Closing of Common Stock Offering 2Dendreon Announces Closing of Common Stock Offering 3Nerviano Medical Sciences Receives Approval From the FDA to Enter Phase I Clinical Trials for Their Polo Like Kinase (PLK) Inhibitor 2GeneCards(R) Version 3.0 Beta Released 2GeneCards(R) Version 3.0 Beta Released 3
(Date:11/4/2009)... 20 Quest Diagnostics In...ider of diagnostic testing, information and servic...tember 30, 2009, income from continuing operations... from $160 million, or $0.81 per diluted share, fo...r results were reduced by a $0.03 per share charge...
(Date:11/4/2009).... 20 Aware, Inc. (Nasdaq...ogy and biometrics software, today reported financ... 30, 2009. ,, Michael Tzannes, Aware,s Chairm...ay, we announced an agreement to sell our DSL and ...less semiconductor company being spun out of Infin...
(Date:11/4/2009)...ct. 23 GenVault Corporation, the l...for genomic discovery, medicine and identification...lt,s President and CEO, will be presenting at the ... 26th and 27th in La Jolla, CA. ,, During the p...f the company together with recent customer, techn...
Breaking Biology News(10 mins):Quest Diagnostics Reports Strong Performance in Third Quarter 2009 2Quest Diagnostics Reports Strong Performance in Third Quarter 2009 3Quest Diagnostics Reports Strong Performance in Third Quarter 2009 4Quest Diagnostics Reports Strong Performance in Third Quarter 2009 5Quest Diagnostics Reports Strong Performance in Third Quarter 2009 6Quest Diagnostics Reports Strong Performance in Third Quarter 2009 7Quest Diagnostics Reports Strong Performance in Third Quarter 2009 8Quest Diagnostics Reports Strong Performance in Third Quarter 2009 9Quest Diagnostics Reports Strong Performance in Third Quarter 2009 10Quest Diagnostics Reports Strong Performance in Third Quarter 2009 11Quest Diagnostics Reports Strong Performance in Third Quarter 2009 12Quest Diagnostics Reports Strong Performance in Third Quarter 2009 13Quest Diagnostics Reports Strong Performance in Third Quarter 2009 14Quest Diagnostics Reports Strong Performance in Third Quarter 2009 15Quest Diagnostics Reports Strong Performance in Third Quarter 2009 16Quest Diagnostics Reports Strong Performance in Third Quarter 2009 17Aware, Inc. Reports Third Quarter 2009 Financial Results 2Aware, Inc. Reports Third Quarter 2009 Financial Results 3Aware, Inc. Reports Third Quarter 2009 Financial Results 4Aware, Inc. Reports Third Quarter 2009 Financial Results 5Aware, Inc. Reports Third Quarter 2009 Financial Results 6Aware, Inc. Reports Third Quarter 2009 Financial Results 7GenVault Corporation to Present at the 2009 BIOCOM Investor Conference 2Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 1Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 2Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 3Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 4GENova gains access to Big Pharma 57148 1GENova gains access to Big Pharma 57148 2GENova gains access to Big Pharma 57148 3Frost 26 Sullivan 3A First Responders Communication Interoperability A Vital Need for Life Saving Services 57146 1Frost 26 Sullivan 3A First Responders Communication Interoperability A Vital Need for Life Saving Services 57146 2
...f the words "parasitic worms," it,s a fact that so...At Michigan State University, researcher Linda Man...vestigating the role that parasites can play in tr...ns. , Her research is part of a more than $10 mil...g the Food and Waterborne Diseases Integrated Rese...
...enomes (IMG) data management system of the U.S. De...) has been released to the public. IMG 1.5 now con...chaeal, 15 eukaryotic genomes and 259 bacterial ph...genomes. , IMG 1.5 contains 62 finished and 100 ...total to 162 microbial genomes generated in-house....
...eloped a new low-cost system that analyzes scatter...plications in medicine, food processing and homela...technologies. , The technique - Bacteria Rapid De...s by shining a laser through a petri dish containi.... , "Unlike conventional methods, we don,t have ...
Other Biology News:Parasitic worms used to fight bowel disease 2DOE JGI releases IMG 1.5 with curated archaeal genomes 2Purdue creates new low-cost system to detect bacteria 2Purdue creates new low-cost system to detect bacteria 3Purdue creates new low-cost system to detect bacteria 4
Mouse Anti-Rat KAPPA / LAMBDA Monoclonal Antibody, Horseradish Peroxidase Conjugated, Clone MARK-1 / MARL-15 from Cell Sciences
Human / Mouse / Rat Chk1 Kinase, active ELISA development Kit, DuoSet, IC (Intracellular) from R&D Systems
Bovine Bovine Serum Albumin, Alexa Fluor 680 conjugated/tagged from Molecular Probes (Invitrogen)
Axl, phospho ELISA development Kit, DuoSet IC Economy Pack from R&D Systems
Biology Products: